Enhance.MD vs. Found: prices, fine print, and the honest verdict

Tirzepatide pricing

Enhance.MD does not offer tirzepatide. Found: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front).

Semaglutide pricing

On semaglutide, Enhance.MD wins at $249 versus $289 all-in — $40/mo apart. Enhance.MD: Semaglutide runs $249 a month all-in at the standing rate ($212 on intro/plan terms). Found: Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms).

Transparency

Enhance.MD: Source-verified (verified 2026-08-08); dispensing pharmacy not publicly named. Found: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Enhance.MD: none month-to-month; term plans paid per schedule. Found: none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front.

Two ladders, side by side

Titration is where these pricing structures stop being abstractions: Found holds $289 on every rung (four-month titration: exactly $1,156). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

On semaglutide, Enhance.MD prices at $249 against $289 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Enhance.MD publishes no figure to normalize; Found's ranked figure is $289, with no membership to add. 2 · Maintenance basis. Found is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Found: standing $289, prepaid $169 effective (12-month plan paid up front) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Enhance.MD: source-verified, read 2026-08-08; Found: third-party-reported, read 2026-08-05. 5 · Pharmacy weighed. Enhance.MD names no pharmacy; Found names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Enhance.MD: no membership — the medication figure is the billed figure; prepaid 12-month plan at $212/mo effective; term plans paid per schedule; commitment: none month-to-month. Found: no membership — the medication figure is the billed figure; prepaid 12-month plan paid up front at $169/mo effective; membership recurs; prepaid terms are paid up front; commitment: none month-to-month; prepaid terms for lowest rate. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Enhance.MD carries source-verified pricing (last read 2026-08-08); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Found carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: Enhance.MD: shipping included; consultation included; async visit model. Found: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Enhance.MD if the semaglutide line is cheaper here. Pick Found if you want a price that survives titration; you'll prepay for the $169 effective rate; you want the insurance paperwork done for you. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Widen the frame one step and the strongest adjacent options are ShedRx at $289 (dose-scaled, no membership); OrderlyMeds at $299 (flat, no membership); SkinnyRx at $299 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,920/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.